Adenomyosis of UterusAdenomyosisNCT07478614
Multicenter Observational Cohort Study on the Epidemiology of Therapeutic Strategies in Patients Affected by Adenomyosis
An observational study of Adenomyosis of Uterus and Uterine Diseases, run by SCHETTINI SERGIO at 1 site in Italy.
Trial summary
The primary objective of this multicenter observational cohort study is to evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence. Read more about this study
- Who is it for?
- Ages 20 to 50 years, women only
- Conditions the study is for
- Adenomyosis of Uterus, Uterine Diseases, Gynecologic Diseases
- What is being tested?
- This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.
- How many people
- 200 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jun 2025to 1 Feb 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Women only
- Adult
Study population: Female patients aged between 20 and 50 years, symptomatic for adenomyosis, with a confirmed diagnosis.
Who may be able to join
- Age between 20 and 50 years; Instrumental (ultrasound or MRI) and/or histological diagnosis of adenomyosis; Adenomyosis-associated pain with a VAS score ≥ 4 and/or presence of heavy menstrual bleeding (HMB) defined as a score > 100 on the Pictorial Blood Assessment Chart (PBAC); Provision of written informed consent to participate in the study; Willingness to be followed at the participating center for the entire duration of the study.
Who cannot join
- Current or previous clinical and/or instrumental diagnosis of endometriosis; Suspected or confirmed pregnancy; Inability to understand the purpose of the study and to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Ospedale San Carlo
Potenza
Sergio Schettini, +39 335424088, schettini@icloud.com
Maria Laura Pisaturo, 3384369617, marialaura.pisaturo@icloud.com
About this study
The primary objective of this multicenter observational cohort study is to evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence. The secondary objective is to identify the criteria guiding therapeutic choices in daily clinical practice within a multicenter setting.
Adenomyosis is a benign gynecological condition characterized by the presence of endometrial-like epithelial and stromal tissue within the myometrium. It mainly affects women aged 41 to 45 years and typically presents with symptoms such as chronic pelvic pain, dysmenorrhea, and menorrhagia. The most commonly used treatments include GnRH agonists, progestins, and intrauterine devices (IUDs); however, there are no universally accepted guidelines for the management of this condition, and therapeutic options remain a matter of debate.
Read more
This is a multicenter observational cohort study with both prospective and retrospective recruitment of women affected by adenomyosis. Italian clinical centers will be included and will recruit patients aged between 20 and 50 years, with a diagnosis of adenomyosis confirmed by ultrasound or magnetic resonance imaging (MRI) and/or histology, and presenting significant symptoms (VAS ≥ 4 for pelvic pain or bleeding > 100 on the Pictorial Blood Assessment Chart - PBAC). Cases of concomitant endometriosis, pregnancy, and conditions preventing informed consent will be excluded.
Each center will collect data regarding the prescribed treatment, its effectiveness, and treatment persistence over time. The study duration will be 12 months, with data collection at baseline (V0), 3 months (V1), 6 months (V2), and 12 months (V3). Approximately 200 patients will be enrolled across 20 centers, with an enrollment period of 12 months.
The analysis will be conducted based on the frequency of treatment use and changes in treatment response in relation to age, symptoms, and other clinical factors.
Data Collection Methodology
Patients will undergo regular clinical evaluations at 3 months, 6 months, and 12 months. Data will be collected using validated questionnaires (VAS, PBAC, SF-12). Transvaginal ultrasound examinations will be performed, and ferritin and hemoglobin levels will be measured. Treatment adherence and tolerability will be monitored through interviews and the recording of adverse events (AEs), including serious adverse events (SAEs).
Data Analysis
The analysis will be descriptive, focusing on the frequency of prescribed treatments and patient characteristics (age, symptoms, comorbidities). Continuous variables will be analyzed using mean and standard deviation (for normally distributed data) or median and range (for non-normally distributed data), while categorical variables will be analyzed using proportions and 95% confidence intervals. Differences between groups will be explored using appropriate statistical tests.
Expected Results and Implications
This study will provide crucial information on the epidemiology of therapeutic approaches to adenomyosis in Italy, helping to bridge existing knowledge gaps and supporting the development of evidence-based recommendations for clinical management. The results will help guide medical practice, improve patients' quality of life, and contribute to the development of therapeutic guidelines.
Dissemination of Results
The study results will be published in scientific articles in international peer-reviewed journals, with active participation of the physicians involved in the research.
- Being tested
- This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.
- Medical subject headings
- Adenomyosis, Uterine Diseases, Genital Diseases, Female, Menorrhagia, Dysmenorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.Other
This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.
What is being measured
The primary outcome is the main question the study is designed to answer.
Epidemiology of Therapeutic Strategies in Patients with Adenomyosis
To evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence.
Measured: Outcomes will be recorded at treatment initiation (baseline) and at 3, 6, and 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Jun 2025
- Primary completion18 Feb 2026
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adenomyosis of UterusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SCHETTINI SERGIO
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, SCHETTINI SERGIO, San Carlo Public Hospital, Potenza, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07478614
- Sponsor's protocol ID
- 20240046096
- Acronym
- Adenomyosis
- Status last verified
- Feb 2026
- First submitted
- 18 Feb 2026
- Last updated
- 17 Mar 2026
- Results posted
- No